{
  "pmcid": "6537634",
  "sha256": "4bb3062345a91ee02fb0b958dbfb5ced2fe5e5a5353f79ac40228c09ffe309a8",
  "timestamp_utc": "2025-11-09T22:51:02.401463+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.943005394297462,
    "reading_ease": 4.751872591831528,
    "word_count": 229
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Minimally Invasive Surgery for Intracerebral Hemorrhage"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was computer-generated with allocation concealment."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults with supratentorial ICH, recruited from multiple centers."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention involved minimally invasive surgery, compared to standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates surgical performance and its impact on intracerebral hemorrhage (ICH) evacuation and functional outcomes."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the modified Rankin Scale (mRS) score of 0 to 3 at 1 year."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "This Phase III randomised controlled trial included 242 participants in the surgical arm of the MISTIE trial."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Analysis was intention-to-treat."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Greater ICH reduction correlated with higher likelihood of achieving mRS 0 to 3, with thresholds of ≤15 mL end-of-treatment ICH volume or ≥70% volume reduction."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}